Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Net revenue	$ 659,191	$ 557,540
Generics
Disaggregation of Revenue [Line Items]
Net revenue	391,294	343,806
Specialty
Disaggregation of Revenue [Line Items]
Net revenue	105,234	91,678
AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	162,663	122,056
International and other | Generics
Disaggregation of Revenue [Line Items]
Net revenue	1,721	301
Anti-infective | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	6,110	5,174
Hormonal / allergy | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	107,714	104,851
Hormonal / allergy | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	29,375	24,763
Antiviral | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	3,866	25,474
Central nervous system | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	109,456	84,582
Central nervous system | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	66,276	60,139
License agreement | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	4,479	0
Cardiovascular system | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	45,878	32,503
Gastroenterology | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	18,197	14,364
Oncology | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	38,533	10,578
Metabolic disease / endocrine | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	11,185	9,265
Respiratory | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	11,136	12,815
Dermatology | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	18,975	18,004
Other therapeutic classes | US | Generics
Disaggregation of Revenue [Line Items]
Net revenue	18,523	25,895
Other therapeutic classes | US | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	5,104	6,776
Distribution | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	109,713	83,230
Government label | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	34,952	24,516
Institutional | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	10,858	8,862
Other | US | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	$ 7,140	$ 5,448